We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
Tilray Brands, Inc. (TLRY - Free Report) closed the most recent trading day at $0.58, moving -8.88% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.33%. Elsewhere, the Dow saw a downswing of 0.63%, while the tech-heavy Nasdaq depreciated by 0.22%.
The stock of company has risen by 53.04% in the past month, leading the Medical sector's loss of 0.32% and the S&P 500's gain of 4.07%.
The investment community will be paying close attention to the earnings performance of Tilray Brands, Inc. in its upcoming release. The company is slated to reveal its earnings on July 28, 2025. The company is predicted to post an EPS of -$0.03, indicating a 25% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $254.8 million, up 10.84% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$1.01 per share and a revenue of $850.75 million, representing changes of -206.06% and 0%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Tilray Brands, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Tilray Brands, Inc. is currently a Zacks Rank #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 156, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors
Tilray Brands, Inc. (TLRY - Free Report) closed the most recent trading day at $0.58, moving -8.88% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.33%. Elsewhere, the Dow saw a downswing of 0.63%, while the tech-heavy Nasdaq depreciated by 0.22%.
The stock of company has risen by 53.04% in the past month, leading the Medical sector's loss of 0.32% and the S&P 500's gain of 4.07%.
The investment community will be paying close attention to the earnings performance of Tilray Brands, Inc. in its upcoming release. The company is slated to reveal its earnings on July 28, 2025. The company is predicted to post an EPS of -$0.03, indicating a 25% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $254.8 million, up 10.84% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$1.01 per share and a revenue of $850.75 million, representing changes of -206.06% and 0%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Tilray Brands, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Tilray Brands, Inc. is currently a Zacks Rank #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 156, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.